User login
Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).
Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.
Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.
Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.
Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source
Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).
Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.
Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.
Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.
Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source
Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).
Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.
Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.
Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.
Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source